Compare JBLU & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JBLU | HRMY |
|---|---|---|
| Founded | 1998 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | 2002 | 2020 |
| Metric | JBLU | HRMY |
|---|---|---|
| Price | $4.42 | $28.39 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 12 | 10 |
| Target Price | $5.20 | ★ $46.70 |
| AVG Volume (30 Days) | ★ 14.5M | 1.1M |
| Earning Date | 04-27-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.83 | 7.97 |
| EPS | N/A | ★ 2.71 |
| Revenue | ★ $9,062,000,000.00 | $868,453,000.00 |
| Revenue This Year | $10.10 | $19.87 |
| Revenue Next Year | $7.91 | $12.49 |
| P/E Ratio | ★ N/A | $10.46 |
| Revenue Growth | N/A | ★ 21.51 |
| 52 Week Low | $3.34 | $25.52 |
| 52 Week High | $6.46 | $40.87 |
| Indicator | JBLU | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 33.25 | 31.77 |
| Support Level | $4.04 | $26.36 |
| Resistance Level | $4.88 | $37.38 |
| Average True Range (ATR) | 0.34 | 1.82 |
| MACD | -0.19 | -0.21 |
| Stochastic Oscillator | 7.67 | 21.42 |
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It served approximately 100 destinations in the United States, the Caribbean and Latin America, Canada, and England. The company currently operates Airbus A321, Airbus A320, Airbus A321neo, and Embraer E190 aircraft types. The company has one operating segment, Air Transportation Services, which provides services in the United States, the Caribbean, Latin America, Canada, and Europe. The majority of revenue is generated from the Domestic & Canada segment.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.